90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...

SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics (APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ...

Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) in advanced-stage classical Hodgkin lymphoma. CA209-8UT randomized 994 ...

Fifteen healthcare organizations, including Loma Linda University Medical Center, have been selected to participate in a national study intended to enhance patient safety and quality of care in health ...

At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients ...

NEW ORLEANS ― An interdisciplinary pilot program effectively deals with behavioral disturbances arising from delirium, dementia, or other mental illnesses in hospitalized older adults ― while keeping ...

Using quadruplet regimens with anti-CD38 monoclonal antibodies, such as daratumumab (Darzalex) or isatuximab (Sarclisa), has significantly advanced frontline therapy for both transplant-eligible and ...

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy "These data from the ...

Michael Kasson, Administrator at Elara Caring, has been named to the Frontline Honors Awards Class of 2025 by Home Health Care News. To become a ...